Abstract

The present invention relates to an engineered scFv comprising an albumin-binding moiety and one or more non-natural amino acids, and an engineered scFv conjugate. The engineered scFv includes non-natural amino acids having a click chemistry functional group, and can be conjugated to a substance having another click chemistry functional group.

IPC Classes  ?

• A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
• A61P 35/00 - Antineoplastic agents

Abstract

Disclosed herein is a multimeric protein-albumin conjugate. The multimeric protein-albumin conjugate has a multimeric protein variant conjugated with albumin via a linker. In the multimeric protein-albumin conjugate, a certain number of albumins are conjugated via a linker to a multimeric protein variant that has an amino acid sequence properly modified to form a conjugate in a site-specific manner. The multimeric protein variant results from substitution of a non-natural amino acid for one or more amino acids in the amino acid sequence of the corresponding wild-type multimeric protein, wherein the linker and albumin is linked to the non-natural amino acid residue.

IPC Classes  ?

• A61K 47/64 - Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
• A61K 47/65 - Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers

Abstract

The present specification discloses a urate oxidase-albumin conjugate, a preparation method thereof, a urate oxidase variant contained in the urate oxidase-albumin conjugate, and a preparation method thereof. The urate oxidase-albumin conjugate is characterized in that three or more albumins are conjugated to the urate oxidase variant through a linker, thereby improving half-life and reducing immunogenicity. In addition, the urate oxidase-albumin conjugate can be used to prevent or treat various diseases, disorders and/or indications caused by uric acid.

IPC Classes  ?

• A61K 38/44 - Oxidoreductases (1)
• A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
• A61K 47/60 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
• A61K 47/64 - Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
• A61P 19/06 - Antigout agents, e.g. antihyperuricemic or uricosuric agents
• C12N 9/06 - Oxidoreductases (1.), e.g. luciferase acting on nitrogen containing compounds as donors (1.4, 1.5, 1.7)

Abstract

The present specification discloses a urate oxidase-albumin conjugate, a preparation method thereof, a urate oxidase variant contained in the urate oxidase-albumin conjugate, and a preparation method thereof. The urate oxidase-albumin conjugate is characterized in that three or more albumins are conjugated to the urate oxidase variant through a linker, thereby improving half-life and reducing immunogenicity. In addition, the urate oxidase-albumin conjugate can be used to prevent or treat various diseases, disorders and/or indications caused by uric acid.

IPC Classes  ?

• A61K 38/44 - Oxidoreductases (1)
• A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
• A61K 47/60 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
• A61K 47/64 - Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
• A61P 19/06 - Antigout agents, e.g. antihyperuricemic or uricosuric agents
• C12N 9/06 - Oxidoreductases (1.), e.g. luciferase acting on nitrogen containing compounds as donors (1.4, 1.5, 1.7)

Abstract

The present application relates to an arginine decarboxylase variant and a functional polypeptide variant-albumin conjugate prepared using same.

IPC Classes  ?

• A61K 38/51 - Lyases (4)
• A61K 47/64 - Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
• A61P 35/00 - Antineoplastic agents

Abstract

The present application provides a functional polypeptide variant-albumin conjugate prepared using an APN group-bearing linker. Furthermore, the present application provides an albumin-linker conjugate, prepared using an APN group-bearing linker, for use in preparing a functional polypeptide variant-albumin conjugate.

IPC Classes  ?

• C07C 255/50 - Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton to carbon atoms of non-condensed six-membered aromatic rings
• C07K 14/765 - Serum albumin, e.g. HSA
• C12N 9/06 - Oxidoreductases (1.), e.g. luciferase acting on nitrogen containing compounds as donors (1.4, 1.5, 1.7)
• A61K 47/64 - Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
• A61K 38/44 - Oxidoreductases (1)
• A61P 19/06 - Antigout agents, e.g. antihyperuricemic or uricosuric agents

Abstract

The present application relates to a method of preparing urate oxidase (Uox) including a non-nature amino acid (NNAA) and Uox prepared thereby. The present application showed that the method of preparing Uox including an NNAA may be effectively used to prolong the half-life of a protein which is difficult to be linked to a carrier. The present application relates to a method of preparing urate oxidase (Uox) including a non-nature amino acid (NNAA) and Uox prepared thereby. The present application showed that the method of preparing Uox including an NNAA may be effectively used to prolong the half-life of a protein which is difficult to be linked to a carrier. In addition, the Uox produced by the method may be effectively used for various biopharmaceuticals since its efficacy is maintained and drug persistency increases due to site-specific conjugation of a carrier, a risk of an immune response is reduced, and it is easily separated due to formation of uniform conjugate.

IPC Classes  ?

• A61K 47/64 - Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
• A23L 33/195 - Proteins from microorganisms
• A61P 13/12 - Drugs for disorders of the urinary system of the kidneys
• A61P 19/06 - Antigout agents, e.g. antihyperuricemic or uricosuric agents
• C12N 9/06 - Oxidoreductases (1.), e.g. luciferase acting on nitrogen containing compounds as donors (1.4, 1.5, 1.7)

Abstract

Arthrobacter globiformisArthrobacter globiformis. The uricase-albumin conjugate is characterized by conjugation of three or more albumins to a uricase variant via linkers, and accordingly exhibits the effects of improving the half-life and reducing immunogenicity. In addition, the uricase-albumin conjugate can be used for the prevention or treatment of various diseases, disorders and/or indications that are caused by uric acid.

IPC Classes  ?

• C07C 255/50 - Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton to carbon atoms of non-condensed six-membered aromatic rings
• C07K 14/765 - Serum albumin, e.g. HSA
• C12N 9/06 - Oxidoreductases (1.), e.g. luciferase acting on nitrogen containing compounds as donors (1.4, 1.5, 1.7)
• A61K 47/64 - Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
• A61K 38/44 - Oxidoreductases (1)
• A61P 19/06 - Antigout agents, e.g. antihyperuricemic or uricosuric agents
• C07K 14/195 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from bacteria
• C07K 14/76 - Albumins

Abstract

The present application relates to a urate oxidase-albumin conjugate and a method for producing same, the urate oxidase-albumin conjugate being produced by binding albumin with a urate oxidase mutant having an unnatural amino acid site-specifically introduced therein. The urate oxidase-albumin conjugate of the present application is produced through a linker comprising a bicyclononyne group.

IPC Classes  ?

• A61K 47/64 - Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
• A61K 47/10 - AlcoholsPhenolsSalts thereof, e.g. glycerolPolyethylene glycols [PEG]PoloxamersPEG/POE alkyl ethers
• A61K 38/44 - Oxidoreductases (1)
• A61P 19/06 - Antigout agents, e.g. antihyperuricemic or uricosuric agents
• A61P 13/04 - Drugs for disorders of the urinary system for urolithiasis
• A61P 13/12 - Drugs for disorders of the urinary system of the kidneys
• C12N 9/06 - Oxidoreductases (1.), e.g. luciferase acting on nitrogen containing compounds as donors (1.4, 1.5, 1.7)

Abstract

The present application relates to a method for producing urate oxidase containing non-natural amino acids, and urate oxidase produced thereby. It was confirmed that the method for producing urate oxidase containing non-natural amino acids disclosed herein allows drug delivery systems to be efficiently connected to proteins, and thus can be effectively used to increase the half-life of proteins to which connecting drug delivery systems was difficult. In addition, the urate oxidase produced by the method is characterized in that a drug delivery system is selectively connected to a specific site such that the efficacy of the urate oxidase is maintained, the drug persistence increases, the risk of immune response decreases, and a uniform conjugate is generated so as to be easy to isolate. Therefore, the urate oxidase can be usefully applied to various biodrugs.

IPC Classes  ?

• A61K 47/64 - Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
• A61K 38/16 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof
• A61P 19/06 - Antigout agents, e.g. antihyperuricemic or uricosuric agents
• A61P 13/12 - Drugs for disorders of the urinary system of the kidneys
• C12N 9/06 - Oxidoreductases (1.), e.g. luciferase acting on nitrogen containing compounds as donors (1.4, 1.5, 1.7)
• A23L 33/195 - Proteins from microorganisms

Abstract

The present application pertains to a peptide-albumin conjugate in which albumin is linked to GLP-1 in a site-specific manner, or a use thereof.

IPC Classes  ?

• C07K 14/605 - Glucagons
• C07K 14/76 - Albumins
• A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
• A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics